We assessed the association between HbA1c and cardiovascular diseases (CVD) in an observational study of patients with type 1 diabetes followed for 5 years.
atients with type 1 diabetes have long been considered to have increased risks of cardiovascular disease (CVD) and mortality (1, 2) , and this has recently been confirmed in two studies from the General Practice Research Database (GPRD) in the UK (3, 4) . Based on data from 1992 to 1999 risks of cardiovascular disease (CVD) and mortality were 4-8 times higher in men and women with type 1 diabetes than non-diabetic individuals (3, 4) . While the association between glycemia and microvascular complications is established (5, 6) , there have been no long-term randomized clinical studies satisfactorily examining the relationship with macrovascular complications in type 1 diabetes, and epidemiological studies have shown conflicting results (7) (8) (9) (10) (11) (12) (13) (14) . The Epidemiology of Diabetes Interventions and Complications (EDIC) study showed that patients who had previously been subject to intensive glucose control during the Diabetes Control and Complications Trial (DCCT) had a considerable lower risk of CVD than patients receiving standard treatment (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (7) . A small study from Finland in late-onset type 1 diabetic patients without albuminuria showed increased risk of coronary heart disease (CHD) with poor glycemic control (9) , but the EURODIAB prospective complications study (PCS), the Pittsburgh Epidemiology of Diabetes Complications study (EDC) and the Wisconsin epidemiologic study of Diabetic Retinopathy, did not demonstrate a significant relationship between glycemia and CHD after controlling for other cardiovascular risk factors (10) (11) (12) (13) . However, a recent study from Pittsburgh EDC showed that change in HbA1c was related to coronary artery disease whereas baseline HbA1c was not (14) . At this background, we assessed the association between HbA1c and CHD, stroke and CVD in a large cohort of patients with type 1 diabetes, 20-65 years of age, treated in everyday clinical practice from 2002 to 2007. Data were used from the Swedish National Diabetes register (NDR), a quality assurance tool in diabetes care with nation-wide coverage, with recently published reports regarding type 1 and type 2 diabetes (15) (16) (17) .
RESEARCH DESIGN AND METHODS
The NDR was initiated in 1996, and annual reporting is carried out by trained physicians and nurses via the Internet or via transfer from clinical records databases, with information collected during patient visits at hospital outpatient clinics and primary care clinics nationwide. All included patients have agreed by informed consent to be registered before inclusion, and all information is subsequently stored in a central database. Subjects. This observational study, approved by The Regional Ethics Review Board at the University of Gothenburg, consists of 7454 female and male patients with type 1 diabetes, with age range 20-65 years, diabetes duration 1-35 years, and data available in the NDR for all analyzed variables. Patients with a history of CVD were not excluded. Baseline clinical characteristics were estimated in 2002-03, and the patients were followed for maximum 5 years until 2007. The epidemiological definition of type 1 diabetes used here was treatment with insulin only and onset age of diabetes 30 years or less. Almost all participants in this study (97%) were treated in hospital clinics. An assessment of type of diabetes performed voluntarily by the reporting clinics, available in 75% of all participants, showed that 97% were assessed to have type 1 diabetes. All participants were divided at baseline in two groups. One group included 4186 patients and was defined to have HbA1c within the interval 5.0-7.9% at baseline of the study, and the other group of 3268 patients had HbA1c within the interval 8.0-11.9%. Both groups P were followed-up for cardiovascular diseases during 5 years. Examinations at baseline. Clinical characteristics evaluated at baseline were sex, age and diabetes duration (years), HbA1c (%), weight (kg), height (m), systolic blood pressure (mmHg), total cholesterol, LDLcholesterol and triglycerides (mmol/l), smoking, microalbuminuria and macroalbuminuria (µg/min). Body mass index (BMI, kg/m 2 ) was calculated as weight divided by height squared. The Swedish standard for blood pressure recording, used in the NDR, was the mean value of two supine readings (Korotkoff 1-5) with a cuff of appropriate size, after at least 5 min of rest. A smoker was defined as a patient smoking one or more cigarettes per day, or smoking tobacco using a pipe, or who had stopped smoking within the past three months. Laboratory analyses of HbA1c, blood lipids and albuminuria values were carried out at local laboratories. HbA1c analyses are quality assured nationwide by regular calibration with the HPLC Mono-S method. In this study, all HbA1c values were converted to the DCCT standard values using the formula: HbA1c (DCCT) = 0.923 x HbA1c (Mono-S) + 1.345; R 2 = 0.998 (18) . HbA1c was measured at baseline. HbA1c was also measured over time as an updated mean of annual measurements, calculated for each individual from baseline to each year of follow up, with the last observation carried forward for missing data. In case of an event during follow-up, the period for estimating updated mean HbA1c was from baseline to the year before this event occurred. Otherwise this period was from baseline to the censor year. LDL cholesterol values were calculated using Friedewald's formula: LDL cholesterol = total cholesterol -HDL cholesterol -(0.45 x triglycerides), if triglycerides <4.0 mmol/l (19). Albuminuria was defined as micro-or macroalbuminuria. Microalbuminuria was defined as urine albumin excretion 20-200 µg/min in two out of three consecutive tests, and macroalbuminuria as u-albumin excretion >200 µg/min. Follow-up, definition of endpoints. All patients were followed from baseline until a cardiovascular event or death, or otherwise until censor date 31 December 2007. Mean follow-up was 4.95 years. The following endpoints were used: fatal/non-fatal CHD, fatal/non-fatal stroke, and fatal/non-fatal CVD. Fatal CHD was defined as ICD-10 codes I20-I25 (http://www.who.int/ classifications/icd/en/). A non-fatal CHD event was defined as non-fatal myocardial infarction (ICD-10 code I21), unstable angina (ICD-10 code I20.0), percutaneous coronary intervention and/or coronary artery bypass graft. Fatal/non-fatal stroke was defined as fatal or non-fatal intracerebral haemorrhage, cerebral infarction or unspecified stroke (ICD-10 codes I61, I63, I64 and I67.9). Fatal/non-fatal CVD was fatal/non-fatal CHD or stroke, whichever came first. All endpoint events were retrieved by data linkage with the Swedish Cause of Death and Hospital Discharge Registers (National Board of Health and Welfare, Sweden), which is a reliable validated alternative to revised hospital discharge records and death certificates (20,21). Statistical methods. Mean values with 1 standard deviation (SD) and standard error (SE) and frequencies (%) with SE of baseline characteristics, and numbers and incidence rates (events per 1000 person-years) of outcomes, are given in Table 1 . Significance of differences was estimated with student t-test for mean values, X 2 test for frequencies, and log rank test at survival analysis for outcome incidences.
Cox regression estimated was used to estimate hazard ratios with 95% confidence intervals (CI) for HbA1c as a continuous variable, or for a lower HbA1c interval versus a higher, and the outcomes (Table 2) , adjusted for covariates as given in the table. The updated mean HbA1c value was treated as a strictly time dependent variable in the Cox regression to evaluate glycemic exposure during follow-up, allowing to use the most recent value of updated mean HbA1c at each specific point of time in the modeling process. In case of an event during follow-up, the period for estimating updated mean HbA1c was from baseline to the year before this event occurred. Otherwise this period was from baseline to the censor year. The proportional hazards assumption was confirmed for all covariates with the Kolmogorov-type supremum test using resampling, and with the test of all timedependent covariates simultaneously. Maximum likelihood estimation was used to evaluate interaction between HbA1c and all covariates, with no significant interaction found. A Cox regression model was also used to estimate 5-year event rates (1 -survival rate) for cardiovascular diseases (Figure 1) , where model output was the adjusted 5-year event rate in each participant, adjusted for covariates as given in Table 2 . Stratification (SAS Phreg: Strata) was performed to achieve adjusted mean event rates by groups or deciles of lower and higher HbA1c (Table 2, Figure 1 ). Sub-grouping of event rates by sample intervals has also been used in a Framingham study (22) . The significance of the difference in mean event rates between lower and higher HbA1c groups was estimated with student's t-test, after logarithmic transformation of event rates to achieve a normal distribution. All statistical analyses were performed using SAS version 9.1.3 (SAS Institute, US). P<0.05 was considered statistically significant.
RESULTS
Baseline characteristics. Table 1 shows baseline characteristics in all 7454 patients. The age range was 20-65 years (mean 37), and the range of diabetes duration 1-35 years (mean 20), mean HbA1c was 8.0%. Albuminuria was present in 20%, and a history of CVD at baseline in 3%. Two patient groups are also shown, 4186 patients with HbA1c at baseline of the study within the interval 5.0-7.9% (mean 7.2%), and 3268 patients within 8.0-11.9% (mean 9.0%). The group with higher HbA1c had somewhat higher mean values of most risk factors, and higher frequencies of smoking and albuminuria. Events. In total 154 fatal or non-fatal CVD events occurred, of which 36 were fatal and 118 non-fatal (Table 1) . Events per 1000 person-years for fatal/non-fatal CHD and CVD in all patients were 4.0 and 4.7 based on 32,931 person-years, higher in the group with higher HbA1c at baseline than in those with lower. The incidence of total mortality was similar in the two HbA1c groups, and considerably more cases were non-CVD mortality than fatal CVD. HbA1c in all patients. Analyzing baseline HbA1c as a continuous variable, Table 2 shows increased hazard ratios (HR) per 1%-unit increase in HbA1c for fatal/non-fatal CHD and CVD: 1.31 (1.12-1.52) and 1.26 (1.09-1.45), p<0.001 after adjustment for age, sex, diabetes duration, systolic blood pressure, smoking, total-and LDLcholesterol, triglycerides, BMI and a history of CVD. These HR for CHD and CVD were only somewhat attenuated after adjustment also for albuminuria: 1.28 (1.09-1.49; p=0.002), and 1.22 (1.06-1.40; p=0.007). HR for fatal/non-fatal stroke and total mortality were non-significant. Using updated mean HbA1c, similar strong associations with CHD and CVD were found. HR for CHD decreased slightly from 1.34 (1.14-1.58; p<0.001) to 1.30 (1.10-1.53; p=0.002) when adjusting also for albuminuria, and HR for CVD decreased from 1.32 (1.14-1.54; p<0.001) to 1.27 (1.09-1.80; p=0.003). Adjusted 5-year event rates of CHD and CVD by baseline HbA1c or updated mean HbA1c ranging from 5% to 12% are presented in Figure  1A -B, showing progressively increasing event rates with higher HbA1c. No elevated risk was seen at the lowest HbA1c levels, as also verified with mean CHD and CVD rates by deciles of updated mean HbA1c ( Figure 1C-D) . When subgrouped by median duration, patients with longer duration 21-35 years (mean 28 years) had a higher adjusted mean rate of CVD, 4.0%, than those with shorter duration 1-20 years (mean 12 years), 0.8%, see Table 2 . Figure 1E -H show progressively increasing rates of CHD and CVD with higher HbA1c in both subgroups. HR for these outcomes per 1%-unit increase in HbA1c were significant in both subgroups. 
CONCLUSION
This large observational study of younger and middle-aged patients (20-65 years) with type 1 diabetes of varying duration, treated in everyday clinical practice, demonstrates a strong association between HbA1c and both CHD and CVD. Each 1% unit increase in baseline HbA1c or updated mean HbA1c was associated with risk increases of 31-34% for CHD and 26-32% for CVD, after adjustment for age, sex, diabetes duration and traditional cardiovascular risk factors. These increases in risk remained significant but were slightly attenuated to 28-30% and 22-27%, respectively, after adjustment also for albuminuria. Fully adjusted 5-year event rates of CHD and CVD increased progressively with higher HbA1c levels, and no J-shaped risk curves were seen. The group with mean HbA1c 7.2% at baseline had risk reductions of 41% for CHD and 37% for CVD, compared to the group with mean 9.0%, when followed for 5 years. Most previous comparable epidemiological studies have not demonstrated clear associations between glycemic control and risk of CHD (10, 11, 13, 14) . The EURODIAB PCS (11) and the Pittsburgh EDC trials (10, 14) were smaller with respect to the numbers of participating patients, although the follow-up periods were longer. The mean duration of diabetes was shorter in the EURODIAB PCS, while similar to our study in the Pittsburgh EDC. In our study, two subgroups by the median duration are presented, with 1-20 years and 21-35 years of duration. Although those with longer duration had higher mean rates of CHD and CVD, the event rate curve increased progressively with higher HbA1c in both subgroups, verified by significant HR for these outcomes per unit HbA1c increase. Interestingly, there was no increase in risk at low HbA1c levels even with longer duration, a possibility that has been discussed in generally older patients with type 2 diabetes (23). The DCCT/EDIC study provides the most convincing evidence regarding glycemic control and risk of CVD in type 1 diabetes (7). Patients were randomized to intensive or standard treatment and followed for 6 years during DCCT. In the subsequent observational EDIC study of 1182 patients, two groups with mean HbA1c 7.4% and 9.1% (mean age 34 years, mean duration 12 years, and albuminuria 7% vs. 13%) were followed for another 11 years regarding CVD outcomes, and totally 144 CVD events occurred in 83 patients. Risk reductions of 42% for any first incident cardiovascular disease and 57% for fatal/non-fatal CVD with lower HbA1c was found at univariate survival analysis (p=0.02), unadjusted for albuminuria. We found a risk reduction of 41% for CVD, unadjusted for albuminuria, in the group with mean HbA1c 7.2%, compared to those with mean 9.0% (p=0.002). Both studies showed similar difference in baseline mean HbA1c of 1.7-1.8% between the groups, similar mean ages and generally quite comparable baseline risk factor levels. Mean duration and frequency of albuminuria were slightly higher in this study. The confounding effect of the inclusion of 3% of all patients with a history of CVD in this study, reasonably also present in the normal patient population treated in clinical practice, was adjusted for at the Cox regression. Our study on data from 2002 to 2007 provides strong support to the results of EDIC conducted from 1994 to 2005. Furthermore, a significant risk reduction for CHD with improved glycemic control was demonstrated here, while not in DCCT/EDIC. The present study also emphasizes the role of albuminuria as a risk factor for CVD in type 1 diabetes. It has been suggested that glycemia is a more potent risk factor of macrovascular disease in the absence of albuminuria (9, 14, 24, 25) . In our study, the hazard ratios for CHD and CVD were 1.31 and 1.26 per 1%-unit increase in baseline HbA1c when adjusted for important CVD risk factors except albuminuria (p<0.001), and were attenuated to 1.28 and 1.22 when adjusted also for albuminuria (p=0.002-0.007). The hazard ratio for CVD with the group of lower HbA1c was 0.59 when unadjusted, but attenuated to 0.63 when adjusted for albuminuria. In the Cox regression analysis of the DCCT/EDIC, the hazard ratio for the intensive treatment group effect on CVD was 0.53 when adjusted only for risk factors at DCCT baseline (p=0.005), but attenuated to 0.58-0.62 when adjusting also for in-treatment differences in albuminuria between the groups during the EDIC follow-up (p=0.02-0.04). Thus, both risk factors are important, and furthermore, their effects on risk seem to be additive as we found no interaction between them. Although observational studies generally are regarded as evidence of lower degree than randomised controlled trials, such trials often use strict inclusion and exclusion criteria, which may limit their application to the normal patient population. This study allowed for an analysis of patients with daily treatment at hospitals nationwide during the recent years with no exclusion criteria regarding risk factors or history of CVD. A major strength of this study was the large number of patients and person-years, and it has not as yet been possible to perform randomised trials of tight glycemic control in type 1 diabetes with a larger number of participants included. It is important to adjust for confounding variables in an observational study and such adjustments were made for age, sex, duration, several traditional cardiovascular risk factors, including albuminuria representing microangiopathy, as well as history of CVD. Analysis of interactions are also important for reliable results, and we could exclude heterogeneity as there were no significant interactions between HbA1c and all included covariates. The capture of data on the outcomes was based on reliable and validated national registers of morbidity and mortality. There were also limitations. Although substantial adjustments was made for confounding variables, unmeasured confounding may exist because of unknown and not included covariates. Data from participating centers may vary slightly in accuracy, although increased use of computer software with direct transfer of data is reducing this problem. Laboratory analyses are carried out in local laboratories, but there is a nationwide program to allow calibration of HbA1c to a standard, and there have only very marginal changes in the cross-sectional mean HbA1c values during the study period. There is also currently no information on autonomic neuropathy, frequency or severity of hypoglycemia, or detailed information on types of insulin used or doses in the NDR. In conclusion, this observational study in a large number of type 1 diabetes patients in modern everyday clinical practice demonstrates a strong independent effect of increased baseline or updated mean HbA1 values on risks of CHD and CVD, with no sign of a J-shaped curve at lower HbA1c values even with longer diabetes duration. A risk reduction of around 40% for CHD and CVD was found when a group with HbA1c mean 7.2% at baseline and followed for 5 years was compared with a group with baseline mean 9.0%. This emphasizes the role of HbA1c as a strong independent risk factor in type 1 diabetes.
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